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Abstract
Background: This study was conducted to evaluate the efficacy of the herbal formula PM012 on an Alzheimer’s
disease model, human presenilin 2 mutant transgenic mice (hPS2m), and also to evaluate the toxicity of PM012 in
Sprague-Dawely rats after 4 or 26 weeks treatment with repeated oral administration.
Methods: Spatial learning and memory capacities of hPS2m transgenic mice were evaluated using the Morris
Water Maze. Simultaneously, PM012 was repeatedly administered orally to male and female SD rats (15/sex/group)
at doses of 0 (vehicle control), 500, 1,000 and 2,000 mg/kg/day for 4 or 26 weeks. To evaluate the recovery
potential, 5 animals of each sex were assigned to vehicle control and 2,000 mg/kg/day groups during the 4-week
recovery period.
Results: The results showed that PM012-treated hPS2m transgenic mice showed significantly reduced escape
latency when compared with the hPS2m transgenic mice. The repeated oral administration of PM012 over 26
weeks in male and female rats induced an increase and increasing trend in thymus weight in the female treatment
groups (main and recovery groups), but the change was judged to be toxicologically insignificant. In addition, the
oral administration of the herbal medicine PM012 did not cause adverse effects as assessed by clinical signs,
mortality, body weight, food and water consumption, ophthalmology, urinalysis, hematology, serum biochemistry,
blood clotting time, organ weights and histopathology. The No Observed Adverse Effects Levels of PM012 was
determined to be 2,000 mg/kg/day for both sexes, and the target organ was not identified.
Conclusion: These results suggest that PM012 has potential for use in the treatment of the Alzheimer’s disease
without serious adverse effects.
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Background
Alzheimer’s disease (AD) is the major cause of dementia
and underlies more than 60% of dementia cases [1]. AD
occurs more frequently in older age groups [2]. AD is
characterized by the impairment of cognitive perfor-
mance such as attention, memory and learning, in addi-
tion to changes in cholinergic markers, including levels
of acetylcholine (ACh) and choline acetyltransferase
(ChAT) [3-5]. In addition, b-amyloid precursor protein
(b-APP), Presenilin 1 (PS1), Presenilin 2 (PS2), and apo-
lipoprotein E type 4 (APOE-E4) mutations are linked to
the early onset of AD [6-10]. Of these, the mutated PS
genes were observed in the highest proportion of early
AD patients [6,11].
Herbal medicines are used for the prevention and
treatment of various diseases. For example, Ginkgo
biloba, Ginseng and Melisa officinalis have been com-
monly used as memory or cognition enhancers. The
effects of these enhancers have been demonstrated
scientifically [12-14]. Yukmijihwang-tang or Luweidi-
huang-wang (YMJ) is composed of 6 herbal medicines,
Corni fructus, Rehmannia radix, Hoelen, Discoreae
radix, Mountain cortex radicis and Alismatis radix. YMJ
has long been applied to the treatment of diabetes melli-
tus and neurosis. Ancient Chinese herbal textbooks also
reference YMJ as an anti-aging treatment. In a previous
study, YMJ derivatives (PM012) containing Lycii fructus,
in addition to the other components of YMJ, enhanced
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enhancing cell proliferation and neurite growth [15]. In
addition, PM012 accelerated the speed of information
processing and enhanced cognitive abilities in normal
subjects [16]. It has also been reported that PM012
treatment prevents the loss of cholinergic cells through
anti-oxidative and anti-inflammatory effects, recovers
reduced ChAT in the medial septum and improves
overall spatial learning ability and the working memory
deficits produced by ibotenic acid [17-19]. However,
because the chemically induced dementia models do not
mimic the pathophysiology of Alzheimer’s disease in
humans, it is necessary to evaluate a more clinically
relevant and straightforward disease model such as
hPS2m transgenic mice. Further, there are no reports
regarding the safety of YMJ or PM012 to date. There-
fore, we here report the results of our investigation of
the safety and efficacy of the PM012 extract in rodents.
This study was conducted in compliance with the Good
Laboratory Practice (GLP) [20] and Test Guidelines of
the Organization for Economic Cooperation and Devel-
opment (OECD) [21] and U.S. Food and Drug Adminis-
tration (FDA)[22] and the Korea Food and Drug
Administration (KFDA) [23].
Methods
Transgenic mice
The human presenilin 2 (hPS2) mutant (N141I) trans-
genic mice (hPS2m) were generously provided by the
National Institute of Toxicological Research (Korea
FDA) and housed in a controlled environment (12:12-
hour light:dark cycle, temperature 23 ± 2°C, humidity 50
± 10%) with water and food available ad libitum.T h e
mice were randomly assigned to two groups (4-5 mice
in each group), defined as follows: group 1: hPS2m tg;
group 2: hPS2m tg + drug treatment. The hPS2m trans-
genic mice received a commercial mice chow, while the
drug treated-hPS2m transgenic mice had access to chow
containing 2% PM012. They were each fed their respec-
tive chow from 32 to 48 weeks of age during the grow-
ing period. All experiments in this study were approved
by the Institutional Animal Care and Use Committee of
Kyung Hee University.
Morris water maze test
A modified version of the procedure described by Mor-
ris was used [24]. The water maze was a circular pool
1.5 m in diameter, constructed of fiberglass. The pool
contained water maintained at a temperature of 22 ± 2°
C and contained 1 kg of powdered skim milk to make
the water opaque. During the testing in the water maze,
a platform (15 cm in diameter) was fixed at 1 cm below
the surface of the water at identical locations within the
pool. The pool was surrounded by different extra-maze
cues. Each trial was initiated at one of different starting
positions and the route taken out of the pool and swim-
ming path of each rat were recorded with a video cam-
era connected to a video recorder and a tracking device
(S-MART, Pan-Lab, Spain). All mice were subjected to
four trials per day at intervals of 15 min for four conse-
cutive days followed by one day of probe trials on the
fifth day. The trials were considered to be completed
when the rat found the hidden platform or the escape
latency reached 60 s. For the probe trial, the platform
was removed from the pool and the rat was allowed to
swim freely for 60 s to search for the previous location
of the platform. The proportion of time spent searching
for the platform in the training quadrant, i.e. the pre-
vious location of the platform, was used as a measure of
memory retention.
Animal maintenance for the toxicity test
According to the Korea FDA guideline, we selected
Sprague Dawley (SD) rats for toxicity assessment.
Seventy male and seventy female SD rats, 5 weeks old,
were obtained from Koatec Co. Ltd (Gyeonggi-do,
Korea). Rats were acclimated in a controlled room (tem-
perature: 23 ± 3°C, relative humidity: 55 ± 15%, air cir-
culating frequency: 10-20 times/hr, artificial light: from
8 am to 8 pm) for 7 days before experimentation. Rats
were housed in stainless steel cages (W215 × L355 × H
200 mm). Animals were offered irradiation-sterilized
pellet food for lab animals (Harlan Co. Ltd, USA), pur-
chased from FOLAS international Inc., ad libitum.
According to the certificates evaluating the diet compo-
nents and contaminants supplied by the diet provider,
there were no factors in the chow that could affect the
results of this study. Groundwater disinfected by ultra-
violet sterilizer and ultrafiltration was given via water
bottle ad libitum. The experimental protocols for this
s t u d yw e r ea p p r o v e db yt h eI n s t i t u t i o n a lA n i m a lC a r e
and Use Committee, and the animals were cared for in
accordance with the institutional ethical guidelines.
Preparation of PM012
Water-extracted dried herbal medicines were purchased
from Sun Ten Pharmaceutical (Taipei, Taiwan). The
ratio of each component in PM012 is shown in Table 1.
The amount of standard phytochemicals of each herbal
medicine was determined by an HPLC-based quantifica-
tion method (Table 1).
Experimental design for toxicity test
Animals were randomly divided into six groups consist-
ing of 15 or 5 rats of each gender. Group I animals
(control) were administered distilled water (DW) by
gavage throughout the course of the study. Animals in
Groups II (500 mg/kg body weight/day), III (1000 mg/
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V (recovery control) and VI (recovery group, 2000 mg/
kg body weight/day) received orally administered
PM012 dissolved in DW by gastric intubation for a per-
iod of 4 or 26 weeks. Urinalyses were conducted during
the last 4 days of the administration period. The urine
of each group of animals was collected for 24 h and the
volume of urine was measured. Animals were individu-
ally placed in metabolic cages in batches for a period of
24 h and were provided with water but not food. The
animals were only fasted in metabolic cages for a period
of 24 h. Food and water were provided ad libitum dur-
ing the other 3 days of sampling of the other groups.
Following the observation period, all animals were
anesthetized with 5 mg/kg of ketamine HCl intramuscu-
larly (Ketamine
®, Yuhan Co., Korea). An autopsy was
conducted on every animal and all major organs and tis-
sues including heart, lung, liver, stomach, intestine, kid-
ney, adrenal gland, spleen and ovary or testicle were
examined for gross lesions.
Clinical observations and survival
Rats were observed twice daily (morning and afternoon)
for signs of clinical toxicity and mortality. Body weights
were recorded daily throughout the study period. Mean
daily food consumption was calculated each day by sub-
tracting the weight of the remaining food from the
weight of the supplied food. Clinical examinations were
performed twice daily, first at the time of dose adminis-
tration and again approximately 1-2 h following dose
administration. Observations included changes in skin,
fur, eyes, oral mucosa, respiration, circulation and
behavior.
Urinalysis
In the last week of observation, 15 animals per group
were housed in a metabolic cage for urine collection,
and approximately 1 ml of fresh urine collected over 3-4
hours was analyzed by urinalysis test strips (Multistix
10SG, Bayer, USA) and an automatic analyzing instru-
ment (CliniTek 100, Bayer, USA). The following para-
meters were analyzed: glucose, bilirubin, ketone bodies,
specific gravity, occult blood, pH, protein, urobilinogen,
nitrite and leukocytes. Samples were also examined
microscopically for the presence of urinary sediments,
including erythrocytes, leukocytes, epithelial cells and
cast.
Hematology and serum biochemistry
Blood samples were measured for clotting time, red
blood cell (RBC) and white blood cell (WBC) counts,
hemoglobin (Hb), hematocrit (HCT), mean corpuscular
volume (MCV), mean corpuscular Hb (MCH), mean
corpuscular Hb concentration (MCHC), red cell distri-
bution width (RDW), Hb concentration distribution
width (HDW), reticulocytes (RET), platelets (PLT),
mean platelet volume (MPV), large unstained cells
(LUC), neutrophils (NEU), lymphocytes (LYM), mono-
cytes (MONO), eosinophils (EOS), and basophils
(BASO) with a Coulter counter (ADVIA 2120, SIE-
MENS, USA) according to the manufacturer’so p e r a t o r
manual. Serum from blood samples collected in
separator tubes was analyzed for changes in biochemis-
try using an AU400 Serum biochemistry analyzer
(AU400, Olympus, Japan), which measured aspartate
aminotransferase activity (AST), alanine aminotransfer-
ase activity (ALT), alkaline phosphatase activity (ALP),
creatine phosphokinase activity (CPK), total bilirubin
(BIL), glucose (GLU), total cholesterol (CHO), trigly-
cerides (TG), total protein (PRO), albumin (ALB), the
albumin/globulin ratio (A/G ratio), blood urea nitrogen
(BUN), creatinine (CRE), and inorganic phosphorus
(IP). The concentrations of calcium ions (Ca
2+),
sodium ions (Na
+), potassium ions (K
+), and chloride
ions (Cl
-) were measured with an electrolyte autoanaly-
zer (RAPIDCHEM 744 Na
+/K
+/Cl
- Analyzer, SIE-
MENS, USA).
Blood clotting time assessment
A total of 1.8 mL of blood was dispensed into a micro-
tube containing 0.2 mL 3.2% sodium citrate. Plasma was
obtained by centrifugation at 735 × g (5402, Eppendorf,
Germany, 3,000 rpm, 735 RCF) at 4°C for 10 min. Pro-
thrombin time (PT) and activated partial thromboplastin
time (APTT) were measured in seconds from the
plasma using the nephelometric analysis method with a
Table 1 The contents of PM012 and the amounts of standard materials
Herbal medicines Ratio (%) Standard materials Standard material contents (mg/PM012 g ext.)
Lycii fructus 4 (26.5%) Betain 0.32 ± 0.02 (0.03%)
Rehmannia radix 4 (26.5%) 5-HMF 0.20 ± 0.02 (0.02%)
Corni fructus 2 (13%) Loganin 1.29 ± 0.05 (0.13%)
Discoreae radix 2 (13%) Allantoin 1.31 ± 0.21 (0.13%)
Hoelen 1 (7%)
Alismatis radix 1 (7%)
Mountain cortex radicis 1 (7%) Paeonol 0.93 ± 0.033 (0.09%)
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Laboratory, USA).
Organ weights
During the necropsy, the organs such as ovaries (both),
uterus, adrenal glands (both), pituitary gland, thymus,
prostate gland, testes (both), epididymides (both), spleen,
kidneys (both), heart, lungs, brain, and liver were
weighed with an electronic balance, and all the paired
organs were measured separately. The weights of these
organs were converted to relative organ weights based
on the organ-to-body weight ratio.
Fixation and storage of organs
Eye balls were fixed in Davidson’s solution, and testes
and epididymides were fixed in Bouin’ss o l u t i o n .T h e
following organs of all animals were fixed in 10% neutral
formalin: testes, epididymides, seminal vesicles, prostate
gland, ovaries, uterus, vagina, urinary bladder, spleen,
stomach, pancreas, duodenum, jejunum, ileum, cecum,
colon, rectum, mesenteric lymph node, adrenal glands,
kidneys, liver, skeletal muscle, sciatic nerve, femur, sub-
mandibular lymph nodes, salivary glands, sternum, thy-
mus, heart, lungs, aorta, thoracic spinal cord, tongue,
trachea, esophagus, thyroid glands, harderian glands,
eyes, brain, pituitary gland, and skin (mammary glands).
Histopathological assessment
The fixed organs of the vehicle control and high dose
group and any organs from the other groups that dis-
played gross abnormalities were subjected to histopatho-
logical examination. Tissues were embedded in paraffin
and microsections of 4-5 μm were taken from the block.
Hematoxylin & Eosin-stained slides were prepared and
the specimens were microscopically examined with an
optical microscope.
Statistical analysis
Statistical analysis of the data was conducted using SPSS
10.1. Data were analyzed by an unpaired t-test or two-
way ANOVA or one-way analysis of variance (ANOVA)
followed by the Dunnett multiple comparisons test.
Results with a p-value < 0.05 were considered statisti-
cally significant.
Results
Efficacy assessment
Effects of PM012 on the body weight of hPS2m transgenic
mice
To determine whether PM012 treatment causes side
effects, we measured its effects on body weight. As
s h o w ni nF i g u r e1 ,t h e r ew e r esignificant differences in
body weight between the hPS2m transgenic mice and
the drug treated-hPS2m transgenic mice [F (1, 70) =
21.21, p < 0.001]. The increase in body weight over the
experimental period was significantly higher in the drug
treated-hPS2 transgenic mice compared to the hPS2m
transgenic mice (t-test; t = 3.387, df = 18, p = 0.0033).
The average body weight of the hPS2m transgenic mice
versus the drug treated-hPS2m transgenic mice was
23.180 ± 1.476 g versus 29.175 ± 0.638 g at 0 week,
27.620 ± 1.930 g versus 29.625 ± 0.819 g at 2 weeks,
29.940 ± 1.857 g versus 33.675 ± 0.735 g at 4 weeks,
30.320 ± 1.777 g versus 33.900 ± 0.998 g at 6 weeks,
30.680 ± 1.810 g versus 34.375 ± 1.005 g at 8 weeks,
32.300 ± 1.731 g versus 35.100 ± 1.027 g at 10 weeks,
32.420 ± 1.704 g versus 35.400 ± 1.002 g at 12 weeks,
32.540 ± 1.745 g versus 35.700 ± 0.99 g at 14 weeks,
31.420 ± 1.774 g versus 35.375 ± 0.923 g at 16 weeks
and 31.420 ± 1.774 g versus 34.975 ± 0.863 g at 18
weeks.
PM012 reverses spatial learning deficits at 12 months of
age in hPS2m transgenic mice
To determine whether PM012 treatment affects spatial
memory tasks, we evaluated its effects on learning and
memory in hPS2m transgenic mice using the Morris
water maze test. In this study, drug treatment had a sig-
nificant effect on escape latency (i.e., the swimming time
required to find a hidden platform in the acquisition
test) and total swimming distance (i.e., the swim path
length taken to find the hidden platform in the acquisi-
tion test) among the hPS2m transgenic mice. The mem-
ory deficiency exhibited by mice with the hPS2m
mutation was significantly alleviated in the drug treated-
hPS2m transgenic mice when compared with the
untreated hPS2m transgenic mice. As shown in Figure
2A and 2A’, analysis of the escape latency revealed a sig-
nificant difference between groups [F (1, 21) = 2.963, p
< 0.05] and depending on the time of day [F (3, 21) =
5.9, p < 0.01]. On days 1-4, the drug treated-hPS2
Figure 1 Change of the body weight of the experimental mice.
The body weight of the hPS2 transgenic mice and the drug
treated-hPS2 transgenic mice at 0, 2, 4, 6, 8, 10, 12, 14, 16 and 18
days following drug treatment (n = 4-5/group). The data shown are
the means ± S.E.M (n = 7-8/group).
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latency when compared with the hPS2 transgenic mice
(t-test; t = 1.762, df = 34, p = 0.0438). As shown in Fig-
ure 2B and 2B’, the total swimming distance differed
significantly among groups [F (1, 21) = 7.70, p < 0.05].
On days 1-4, the drug treated-hPS2 transgenic mice
showed a significantly reduced escape latency when
compared with the hPS2 transgenic mice (t-test; t =
2.183, df = 34, p = 0.0180). Conversely, there was no
significant difference in the average swimming speed
among groups on all training days (data not shown).
The performance on the probe trial, which compared
the percentage of time spent swimming around the plat-
form on day 5, is illustrated in Figure 3A. There was no
significant difference in time spent swimming around the
platform among the mice (Figure 3B). The learning and
memory retention performance test revealed that the drug
treated-hPS2 transgenic mice spent a slightly longer time
around the platform than the hPS2 transgenic mice, but
this difference was not significant (t-test; t = 0.1253, df =
7, p = 0.452). These findings indicated that PM012 treat-
ment ameliorated spatial memory impairment in hPS2m
mice without affecting locomotive activity.
Safety assessment
Clinical observations and survival
The rats from all treatment groups appeared to be
healthy at the conclusion of the study period (Table 2).
In general, there were no statistically significant changes
in body weights (Figure 4). There were no significant
differences in food (Figure 5) and water (Figure 6) con-
sumption between the control and treatment groups. In
addition, there were no statistically significant differ-
ences in food and water consumption, regardless of sex
or recovery group (Figure 5 and 6). No abnormal find-
ings were found in the ophthalmic examination (data
not shown).
Urinalysis
Semi-quantitative urinary examinations, such as pH,
specific gravity, protein, glucose, urea acid, ketone and
Figure 2 Alteration of escape latency and swimming distance during an acquisition test using the water maze. Four trials per day for 4
consecutive days were conducted and the escape latency (A and A’) and swimming distance (B and B’) were measured. Representative images
(C) showing the swimming path of mice during the tests. Left: drug non treated- hPS2 transgenic mice and right: drug treated-hPS2 transgenic
mice. Data are presented as mean ± SEM, and comparisons between the two groups were evaluated by the unpaired t-test. *P < 0.05 compared
to the drug treated-hPS2 transgenic mice.
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ing acute administration of the PM012 extract (Addi-
tional file 1: Table S1). Moreover, PM012 treatment did
not cause any significant changes in the presence of
urinary sediments (data not shown). In recovery groups,
the urine volume in males treated with 2,000 mg/kg/day
was significantly (P < 0.05) higher than that in the vehi-
cle control group.
Hematology
Hematology data are summarized in Table 3. No statis-
tically significant differences were observed in the hema-
tology parameters, including RBC, PLT, WBC, NEU,
LYM, MONO, EOS, BASO, and LUC counts upon
PM012 treatment. Similarly, there were no significant
changes in clotting time, HDW, Hb, RET, HCT, HGB,
MCV, RDW, MCH, MCHC and MPV values between
the control and treated animals (main groups). In recov-
e r yg r o u p s ,t h ei n c r e a s e si nM C V ,M C H ,H D Wa n d
LYM, and the decrease in NEU observed in females
treated with 2,000 mg/kg/day were statistically signifi-
cant (P < 0.05) compared with the vehicle control group.
Serum biochemistry
Serum biochemistry data are summarized in Table 4.
There were no significant changes in the levels of CPK,
G L U ,C H O ,T G ,A / G ,B U N ,C R Eo rI P .F e m a l em i c e
treated with 2,000 mg/kg/day PM012 extract exhibited
significantly increased PRO. No statistically significant
differences in serum electrolytes such as K
+ or Cl
- were
noted. Male mice treated with 1,000 mg/kg/day PM012
extract exhibited significantly decreased Ca
2+ (main
groups). Moreover, female mice treated with 1,000 mg/
kg/day PM012 extract exhibited significantly decreased
Na
+ (main groups). The effects of PM012 on liver func-
tion parameters such as AST, ALT, ALP, and BIL in
serum were also investigated. Female mice treated with
500 and 2,000 mg/kg/day PM012 extract exhibited sig-
nificantly increased ALB. The 1,000 mg/kg/day exposure
groups and recovery groups, however, did not exhibit
significant changes in serum AST, ALT, ALP or BIL.
Organ weights
Organ weight data are summarized in Table 5. Thymus
weight showed a dose-related increasing trend in the
main and recovery female groups and a significant
increase (P < 0.01) was identified in the 2,000 mg/kg/
day recovery group. No statistically significantly differ-
ences were observed in males
Histopathology
Histopathological examinations are an important aspect
of safety assessments. A macroscopic examination of
vital organs found no abnormalities. Histological evalua-
tion of the adrenal gland, pituitary gland, prostate gland,
kidney, liver, spleen, lung, heart, thymus, thyroid gland,
mesenteric and harderian glands did not reveal any
pathological changes in the highest dose group (data not
shown).
Discussion
Natural products have long been used in traditional
medicine to treat various diseases. Extracts prepared
from medicinal plants and other natural sources contain
a variety of molecules with potent biological activities.
However, it is often difficult to analyze the biological
Figure 3 Alteration of time spent and distance around the platform and during the memory retention test in the water maze.F o u r
trials were conducted on the fifth day without the platform and the search latency (A) and distance (B) were measured. Data are presented as
mean ± SEM, and comparisons between the two groups were made using the unpaired t-test. *P < 0.05, compared to the drug treated-hPS2
transgenic mice.
Table 2 Abnormal clinical signs and mortality in rats
orally treated with PM012
Sex Dose (mg/kg) Observations
0-4 Weeks 0-26 Weeks
Male 0 Appears normal Appears normal
500 Appears normal Appears normal
1000 Appears normal Appears normal
2000 Appears normal Appears normal
Female 0 Appears normal Appears normal
500 Appears normal Appears normal
1000 Appears normal Appears normal
2000 Appears normal Appears normal
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B
C
Figure 4 Mean body weight of male and female rats dosed
with PM012. Each data point represents the mean body weight of
groups of ten or fifteen animals. A) main group receiving 4 weeks
of treatment, B) main group receiving 26 weeks of treatment and C)
4 weeks recovery group. Statistical analysis of the data (Dunnett’s
test) revealed no significance differences between groups.
A
B
C
Figure 5 Mean food consumption by male and female rats
treated with PM012. Each data point represents the mean food
consumption of groups of ten or fifteen animals. A) main group
receiving 4 weeks of treatment, B) main group receiving 26 weeks
of treatment and C) 4 weeks recovery group. Statistical analysis of
the data (Dunnett’s test) revealed no significance differences
between groups.
Sohn et al. BMC Complementary and Alternative Medicine 2012, 12:24
http://www.biomedcentral.com/1472-6882/12/24
Page 7 of 16activities of these extracts because of their complex nat-
ure and the possible synergistic effects of their compo-
nents. Recently, the raw materials of such products have
been used to develop new drugs [1,25,26].
Many studies have reported the pharmacological effi-
cacy of PM012. PM012 was shown to have potent pro-
tection effects against ibotenic acid-induced cell damage
and cognitive deficits in a previous study [27]. In addi-
tion, PM012 treatment accelerated the speed of informa-
tion processing and enhanced cognitive abilities in
normal subjects [28]. PM012 may repair cognitive
impairment induced by dementia through an increase of
acetylcholine synthesis in combination with the other
advantageous effects mentioned above, thus helping to
alleviate the symptoms of dementia patients [15,27,28].
The components of PM012 have been shown to have
various effects when used individually. Mountain cortex
radicis, a component of PM012, decreased ROS genera-
tion and cytotoxicity in hydrogen peroxide-stimulated
neuronal cells through increasing the expression of the
genes heme oxygenase and COMT, which play a major
role in regulating ROS production [29]. Rehmanniae
Radix, another component of PM012, improved learning
and memory in monosodium glutamate-treated rats
through anti-oxidation and increased the expression of
hippocampal c-fos and NGF and intelligence in humans
[2,3]. It has been reported that Lycii Fructus and Corni
fructus, additional components of PM012, have strong
anti-oxidative effects [4,30]. Furthermore, Lycii Fructus
[31], Corni fructus [32], Rehmannia radix [21], Discor-
eae radix [33], and Mountain cortex radicis [34], have
all shown anti-inflammatory effects. However, to date,
there is no information on any aspects, such as oral
toxicity, of the safety of any of these components or
PM012. Therefore, we investigated and here report the
safety of repeated oral administration as determined by
a toxicity experiment conducted with a crude extract of
PM012 using male and female SD rats.
The present study was performed to evaluate the effi-
cacy of PM012 in hPS2m transgenic mice and the toxi-
city of PM012 in SD rats after 4- or 26-week repeated
oral administrations and to identify the no observed
adverse effect level (NOAEL), target organs and the
recovery potential during the 4-week recovery study.
The Morris water maze task was used to test the effect
of PM012 on the relative spatial learning capability and
reference memory in hPS2m mice to determine whether
PM012 can protect against memory impairment. The
Morris water maze spatial learning task has been used
in the validation of rodent models for neurocognitive
disorders and for the evaluation of possible neurocogni-
tive treatments. In the current study, the latency to find
the platform in acquisition trials by the PM012-treated
A
B
C
Figure 6 Mean water consumption by male and female rats
treated with PM012. Each data point represents the mean water
consumption of groups of ten or fifteen animals. A) main group
receiving 4 weeks of treatment, B) main group receiving 26 weeks
of treatment and C) 4 weeks recovery group. Statistical analysis of
the data (Dunnett’s test) revealed no significance differences
between groups.
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Page 8 of 16Table 3 Hematological values in rats orally treated with PM012
Hematological values
Parameter Unit Sex 0 mg/kg 500 mg/kg 1000 mg/kg 2000 mg/kg
4 Weeks 26 Weeks Recovery 4 Weeks 26 Weeks 4 Weeks 26 Weeks 4 Weeks 26 Weeks Recovery
WBC 10
3/
μL
Male 11.12 ±
2.81
8.37 ±
1.35
7.63 ±
2.04
14.14 ±
2.29
9.47 ± 2.14 11.17 ±
3.22
8.35 ±
2.56
10.88 ±
3.18
8.99 ±
1.97
7.70 ±
1.07
Female 6.78 ±
0.78
4.73 ±
0.92
5.82 ±
1.86
7.61 ±
0.75
4.20 ± 0.95 9.15 ±
3.92
4.83 ±
1.50
8.89 ±
2.60
4.93 ±
1.06
5.65 ±
1.43
RBC 10
6/
μL
Male 8.03 ±
0.17
9.04 ±
0.28
8.72 ±
0.38
8.12 ±
0.24
9.12 ± 0.32 8.11 ±
0.20
8.86 ±
0.19
8.24 ±
0.06
8.89 ±
0.27
8.65 ±
0.26
Female 7.99 ±
0.20
8.00 ±
0.25
7.68 ±
0.30
7.72 ±
0.43
8.09 ± 0.27 7.69 ±
0.29
8.12 ±
0.52
7.76 ±
0.18
7.96 ±
0.18
7.61 ±
0.22
HGB g/dL Male 15.38 ±
0.53
15.5 ± 0.3 15.0 ± 0.8 15.40 ±
0.26
15.8 ± 0.5 15.42 ±
0.50
15.2 ± 0.4 15.44 ±
0.33
15.2 ± 0.3 14.9 ± 0.5
Female 14.86 ±
0.41
14.5 ± 0.5 13.7 ± 0.5 14.54 ±
0.52
14.5 ± 0.4 14.50 ±
0.69
14.6 ± 0.7 14.88 ±
0.41
14.4 ± 0.5 14.1 ± 0.4
HCT % Male 43.62 ±
1.40
46.2 ± 1.0 45.2 ± 2.4 43.62 ±
0.87
46.9 ± 1.3 43.76 ±
1.24
45.2 ± 1.4 43.82 ±
1.04
45.1 ± 0.9 44.3 ± 1.1
Female 42.08 ±
0.88
42.5 ± 1.4 40.9 ± 1.4 41.50 ±
1.52
42.8 ± 1.4 40.94 ±
1.30
43.2 ± 1.8 41.74 ±
1.06
42.4 ± 1.2 41.5 ± 1.3
MCV fL Male 54.28 ±
1.10
51.1 ± 1.5 51.9 ± 2.5 53.72 ±
1.45
51.5 ± 1.0 54.00 ±
1.22
51.1 ± 1.1 53.14 ±
1.48
50.8 ± 1.5 51.2 ± 0.9
Female 52.68 ±
0.31
53.1 ± 0.7 53.2 ± 1.0 53.82 ±
1.25
52.9 ± 1.8 53.28 ±
0.75
53.3 ± 2.3 53.84 ±
1.00
53.3 ± 1.2 54.7 ± 0.5
MCH pg Male 19.14 ±
0.43
17.2 ± 0.5 17.3 ± 0.8 19.00 ±
0.47
17.4 ± 0.4 19.06 ±
0.30
17.1 ± 0.3 18.74 ±
0.44
17.1 ± 0.4 17.2 ± 0.3
Female 18.56 ±
0.19
18.1 ± 0.3 17.9 ± 0.2 18.88 ±
0.43
17.9 ± 0.5 18.88 ±
0.40
18.1 ± 0.7 19.18 ±
0.30
18.1 ± 0.5 18.4 ± 0.2
MCHC g/dL Male 35.22 ±
0.18
33.6 ± 0.4 33.3 ± 0.3 35.32 ±
0.57
33.7 ± 0.4 35.28 ±
0.41
33.6 ± 0.4 35.28 ±
0.47
33.7 ± 0.3 33.7 ± 0.4
Female 35.24 ±
0.48
34.1 ± 0.5 33.7 ± 0.2 35.06 ±
0.29
33.9 ± 0.6 35.38 ±
0.90
33.9 ± 0.5 35.58 ±
0.26
34.0 ± 0.4 33.8 ± 0.2
RDW % Male 15.34 ±
0.47
12.3 ± 0.5 12.7 ± 0.6 15.30 ±
1.12
12.4 ± 0.5 15.52 ±
0.40
12.1 ± 0.4 15.24 ±
0.36
12.2 ± 0.3 12.5 ± 0.7
Female 14.84 ±
0.38
11.1 ± 0.4 10.5 ± 0.4 13.96 ±
0.88
11.1 ± 0.5 14.58 ±
0.70
11.2 ± 0.5 14.18 ±
0.33
11.0 ± 0.3 11.0 ± 0.5
HDW g/dL Male ND
a) 2.60 ±
0.14
2.73 ±
0.21
ND
a) 2.68 ± 0.13 ND
a) 2.52 ±
0.18
ND
a) 2.58 ±
0.14
2.53 ±
0.27
Female ND
a) 2.43 ±
0.20
2.20 ±
0.11
ND
a) 2.29 ± 0.18 ND
a) 2.39 ±
0.24
ND
a) 2.36 ±
0.20
2.52 ±
0.23
PLT 10
3/
μL
Male 945.2 ±
81.9
993.3 ±
82.7
10.54 ±
109.3
935.2 ±
37.8
1015.1 ±
107.4
869.6 ±
72.2
992.2 ±
66.3
930.4 ±
72.1
1024.1 ±
97.6
10.84.4 ±
77.0
Female 997.0 ±
72.9
1016.5 ±
90.2
1013.2 ±
62.5
975.0 ±
43.6
1017.7 ±
69.6
997.8 ±
99.9
912.4 ±
264.7
985.6 ±
74.1
997.3 ±
91.4
1019.8 ±
79.7
MPV fL Male 5.83 ±
0.49
5.92 ±
0.27
5.94 ±
0.29
5.67 ±
0.22
5.94 ± 0.20 5.91 ±
0.29
5.82 ±
0.17
5.81 ±
0.20
5.78 ±
0.15
5.98 ±
0.37
Female 5.90 ±
0.33
6.02 ±
0.13
5.88 ±
0.13
5.90 ±
0.09
6.16 ± 0.25 5.67 ±
0.19
7.12 ±
2.44
5.73 ±
0.15
6.36 ±
0.84
5.90 ±
0.19
RET % Male 2.2 ±
0.84
2.22 ±
0.22
2.31 ±
0.28
1.8 ±
0.84
2.20 ± 0.20 2.0 ±
1.41
2.10 ±
0.27
2.4 ±
1.14
2.15 ±
0.26
2.32 ±
0.30
Female 3.4 ±
1.82
2.39 ±
0.33
1.81 ±
0.51
3.8 ±
1.30
2.47 ± 0.36 3.2 ±
1.48
2.30 ±
0.60
2.2 ±
1.64
2.26 ±
0.28
2.36 ±
0.27
NEU % Male 12.75 ±
3.77
26.6 ±
10.7
16.2 ± 4.5 9.81 ±
2.15
29.8 ± 8.9 14.30 ±
4.91
25.2 ±
11.0
13.06 ±
6.29
23.5 ± 7.1 17.5 ± 6.0
Female 10.25 ±
1.99
16.8 ± 4.5 31.3 ±
13.9
9.06 ±
2.03
16.6 ± 2.3 9.87 ±
4.91
17.1 ± 5.3 9.46 ±
2.87
16.3 ± 3.6 15.4 ± 3.7
LYM % Male 79.76 ±
5.96
68.2 ±
10.7
77.2 ± 5.0 84.80 ±
2.56
64.6 ± 8.6 77.52 ±
5.76
69.0 ±
10.5
79.90 ±
7.43
70.6 ± 6.5 74.7 ± 7.8
Female 82.46 ±
3.14
78.0 ± 4.5 61.9 ±
12.5
85.10 ±
2.67
77.6 ± 2.3 83.96 ±
5.54
76.4 ± 6.5 83.84 ±
2.46
77.8 ± 4.0 77.8 ± 4.1
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Page 9 of 16group was significantly decreased compared to the
untreated group. The PM012-treated group also spent a
greater proportion of the probe trial searching in the
training quadrant, demonstrating that PM012 attenuated
the hPS2 mutation-induced learning and memory defi-
cits. Weight loss is a frequent condition of AD, occur-
ring in about 30%-40% of all AD patients [35,36]. Body
weight was significantly increased in the PM012-treated
group, suggesting possible beneficial effects of PM012
on AD progression. In terms of safety, no mortality was
observed and no abnormal changes were observed in
the body weight, food and water consumption, ophthal-
mic examination, urinalysis and blood clotting time test.
In the clinical examination of the rats used in the
safety assessment, some rats presented with anomalous
pathologies but no significant differences were found in
relation to treatment with PM012. A mass observed in
one female treated with 1,000 mg/kg/day was identified
as a fibroadenoma, a benign tumor derived from mam-
mary epithelium and connective tissue. It is a sponta-
neous tumor that is commonly observed in rats [37-39].
In the hematological and serum biochemistry tests, all
changes observed in the female recovery group and
main groups of both sexes were within normal levels
and no significant changes were found in the related
test parameters. In terms of organ weights, the increases
of the absolute and relative weights of the thymus
observed in the female 2,000 mg/kg/day recovery group
were similar to those in the 4-week repeated dose toxi-
city study, and a dose-related increasing trend was
observed in the female main groups. However, no other
abnormal changes of the thymus were observed in the
related test parameters of the histopathological examina-
tion, and therefore the changes were deemed not
toxicologically significant [40]. In the necropsy findings,
changes observed in the main and recovery groups were
spontaneous or agonal congestion/hemorrhage due to
anesthesia and not related to the administration of
PM012.
In the histopathological examination, no noteworthy
PM012-related lesions were observed, though some
abnormalities were found. The lesions observed in the
kidneys, such as glomenulonephropathy, basophilic
tubules in the kidneys and hyaline cast, were high in fre-
quency, primarily in males. However, these symptoms
are part of chronic progressive nephropathy often
observed in rats of approximately 5 months to old age
and is particularly frequently observed in males. This
nephropathy is accompanied by hyaline cast, which
most frequently occurs due to an increase of glomerular
penetrability or disorder renal tubular reabsorption.
Multifocal alveolar histocytosis was observed in the
lungs and is generally characterized by the infiltration of
alveolar macrophages with foamy cytoplasm in the pul-
monary alveoli near terminal bronchial tubes. This
alveolar histocytosis is known to appear when drugs
such as aminodarone and iprindole are administered,
but it also is known to occur spontaneously in the lungs
of rats. All lesions observed in the kidneys and lungs
described above were not considered to be changes trig-
gered by the administration of PM012 based on the
comparison to the vehicle control group [38,39,41].
Furthermore, the diffuse cortical vacuolation observed in
the zona fasciculate of the male adrenal gland, the
accessory adrenocortical tissue observed in the female
adrenal gland, the cyst and pseudocyst observed in the
distal pituitary gland, the focal myocarditis observed
only in the male heart, the follicular cyst and corpus
Table 3 Hematological values in rats orally treated with PM012 (Continued)
MONO % Male 4.40 ±
1.85
3.05 ±
0.36
4.12 ±
1.52
2.77 ±
1.01
3.57 ± 1.09 4.41 ±
1.39
3.52 ±
0.96
3.66 ±
0.97
3.74 ±
0.90
5.36 ±
1.81
Female 3.75 ±
1.08
2.77 ±
0.79
4.24 ±
1.05
2.84 ±
0.80
3.01 ± 0.65 2.90 ±
0.70
3.64 ±
0.98
3.33 ±
0.50
3.68 ±
0.94
3.92 ±
0.33
EOS % Male 0.64 ±
0.27
1.47 ±
0.36
1.52 ±
0.59
0.53 ±
0.32
1.29 ± 0.49 0.64 ±
0.10
1.62 ±
0.62
0.83 ±
0.39
1.40 ±
0.75
1.08 ±
0.42
Female 0.95 ±
0.64
1.67 ±
0.47
1.74 ±
0.58
0.83 ±
0.33
2.04 ± 0.87 0.97 ±
0.52
1.79 ±
0.58
0.88 ±
0.29
1.36 ±
0.37
2.04 ±
0.42
BASO % Male 2.43 ±
0.75
0.12 ±
0.06
0.16 ±
0.05
2.10 ±
0.60
0.15 ± 0.05 3.11 ±
0.44
0.17 ±
0.08
2.56 ±
0.47
0.17 ±
0.07
0.22 ±
0.04
Female 2.58 ±
0.61
0.12 ±
0.06
0.10 ±
0.00
2.18 ±
0.45
0.18 ± 0.15 2.31 ±
0.45
0.16 ±
0.08
2.50 ±
0.56
0.12 ±
0.04
0.12 ±
0.04
LUC % Male ND
a) 0.57 ±
0.22
0.78 ±
0.26
ND
a) 0.63 ± 0.33 ND
a) 0.58 ±
0.15
ND
a) 0.61 ±
0.23
1.14 ±
0.92
Female ND
a) 0.62 ±
0.21
0.74 ±
0.30
ND
a) 0.65 ± 0.35 ND
a) 0.86 ±
0.31
ND
a) 0.72 ±
0.35
0.74 ±
0.28
* WBC: white blood cell, RBC: red blood cell, HGB: hemoglobin concentration, HCT: hematocrit, MCV: mean corpuscular volume, MCH: mean corpuscular
hemoglobin, MCHC: mean corpuscular hemoglobin concentration, RDW: Red cell distribution width, PLT: Platelet, MPV: Mean platelet volume, RET: Reticulocyte,
NEU: Neutrophil, LYM: Lymphocyte, MONO: Monocyte, EOS: Eosinophil, BASO: Basophil. Values are mean ± SD (n = 5 (4 weeks) or 10 (26 weks)/sex/dose). P <
0.05 compare with normal group.
b) ND, not determined.
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Page 10 of 16Table 4 Serum biochemical values in rats orally treated with PM012
Dose (mg/kg)
Parameter Units Sex 0 500 1000 2000
4 Weeks 26
Weeks
Recovery 4 Weeks 26
Weeks
4 Weeks 26
Weeks
4 Weeks 26
Weeks
Recovery
AST U/L Male 113.90 ±
12.59
83.1 ±
11.4
90.0 ±
12.8
101.98 ±
14.09
78.5 ±
9.5
94.46 ±
12.02
85.9 ±
14.5
108.66 ±
24.97
84.1 ±
12.7
85.1 ±
21.5
Female 97.10 ±
12.99
82.0 ±
10.0
83.9 ±
17.6
102.54 ±
16.78
81.9 ±
16.5
102.88 ±
7.01
81.9 ±
16.6
107.64 ±
21.81
80.3 ±
9.7
81.3 ±
13.2
ALT U/L Male 35.06 ±
4.56
50.3 ±
10.5
52.1 ±
10.3
34.10 ±
4.28
44.3 ±
6.6
35.56 ±
4.18
48.8 ±
12.9
34.68 ±
4.66
41.9 ±
6.7
52.6 ±
8.4
Female 27.14 ±
3.54
37.3 ±
7.8
36.4 ± 3.6 25.96 ±
2.36
35.8 ±
3.7
27.64 ±
1.90
33.4 ±
5.6
27.06 ±
1.64
36.1 ±
6.5
35.2 ±
3.9
ALP U/L Male 133.96 ±
13.75
76.7 ±
11.9
84.6 ±
11.9
124.38 ±
9.96
77.0 ±
11.0
126.12 ±
9.52
79.5 ±
14.9
147.08 ±
19.36
73.1 ±
12.2
91.1 ±
9.1
Female 87.20 ±
10.59
57.9 ±
12.2
54.1 ± 8.7 92.66 ±
15.55
62.3 ±
28.8
99.04 ±
18.32
50.6 ±
16.5
88.48 ±
3.48
54.7 ±
11.5
58.4 ±
13.4
CPK U/L Male 408.4 ±
68.2
101.6 ±
25.6
199.8 ±
118.8
291.6 ±
96.3
98.9 ±
20.5
212.4 ±
92.1
114.7 ±
49.5
261.0 ±
152.6
122.8 ±
65.9
135.2 ±
64.9
Female 265.8 ±
110.2
104.1 ±
31.7
143.8 ±
70.5
266.6 ±
142.2
87.2 ±
45.2
227.8 ±
78.6
81.9 ±
28.9
282.0 ±
148.6
85.0 ±
33.1
161.2 ±
68.4
BIL mg/dL Male 0.21 ± 0.00 0.19 ±
0.02
0.19 ±
0.02
0.21 ± 0.00 0.21 ±
0.02
0.20 ±
0.01
0.19 ±
0.01
0.21 ± 0.01 0.20 ±
0.02
0.20 ±
0.01
Female 0.21 ± 0.02 0.23 ±
0.03
0.26 ±
0.04
0.23 ± 0.02 0.23 ±
0.03
0.22 ±
0.02
0.23 ±
0.03
0.23 ± 0.02 0.24 ±
0.02
0.26 ±
0.05
GLU mg/dL Male 102.18 ±
9.12
116.8 ±
9.1
120.5 ±
9.5
99.94 ±
5.77
121.3 ±
12.3
108.70 ±
9.87
113.7 ±
11.4
109.38 ±
8.60
113.3 ±
9.8
121.0 ±
8.4
Female 106.66 ±
7.29
107.6 ±
10.7
130.5 ±
14.1
99.86 ±
3.54
111.6 ±
15.7
100.10 ±
5.58
110.0 ±
11.2
99.30 ±
9.04
106.2 ±
12.2
132.0 ±
7.4
CHO mg/dL Male 90.4 ± 6.6 139.5 ±
27.3
165.0 ±
46.6
93.2 ± 12.8 152.9 ±
46.8
95.6 ± 9.4 123.2 ±
26.6
84.6 ± 9.9 116.0 ±
25.2
180.2 ±
73.0
Female 96.8 ± 13.2 118.9 ±
13.0
119.0 ±
20.9
96.4 ± 20.6 119.1 ±
33.0
98.0 ±
11.6
138.5 ±
34.5
98.2 ± 17.2 126.4 ±
28.2
131.4 ±
24.5
TG mg/dL Male 45.2 ± 8.2 49.6 ±
8.3
54.8 ±
18.9
46.8 ± 11.1 61.1 ±
20.2
44.4 ± 7.1 46.0 ±
10.4
46.4 ± 7.4 47.7 ±
7.3
63.4 ±
34.0
Female 36.0 ± 8.1 43.5 ±
5.5
39.6 ± 5.3 36.4 ± 7.7 43.2 ±
6.6
36.2 ± 4.1 48.1 ±
6.5
39.4 ± 6.5 47.6 ±
9.0
44.0 ±
13.1
PRO g/dL Male 6.04 ± 0.10 6.54 ±
0.14
6.38 ±
0.17
5.99 ± 0.23 6.48 ±
0.19
5.97 ±
0.10
6.42 ±
0.13
5.99 ± 0.24 6.50 ±
0.17
6.60 ±
0.21
Female 5.63 ± 0.23 6.37 ±
0.16
6.84 ±
0.33
5.81 ± 0.38 6.65 ±
0.35
5.71 ±
0.23
6.60 ±
0.30
5.79 ± 0.13 6.76 ±
0.32
6.53 ±
0.20
ALB g/dL Male 3.17 ± 0.05 2.99 ±
0.10
2.85 ±
0.14
3.14 ± 0.08 2.95 ±
0.11
3.15 ±
0.04
2.97 ±
0.07
3.18 ± 0.11 3.07 ±
0.12
2.83 ±
0.21
Female 3.05 ± 0.11 3.16 ±
0.10
3.44 ±
0.26
3.16 ± 0.12 3.34 ±
0.12
3.08 ±
0.09
3.27 ±
0.19
3.14 ± 0.04 3.38 ±
0.20
3.25 ±
0.16
A/G ratio Male 1.10 ± 0.00 0.84 ±
0.03
0.81 ±
0.09
1.10 ± 0.04 0.84 ±
0.08
1.12 ±
0.02
0.86 ±
0.05
1.14 ± 0.03 0.90 ±
0.06
0.76 ±
0.11
Female 1.19 ± 0.05 0.98 ±
0.06
1.01 ±
0.10
1.20 ± 0.10 1.01 ±
0.05
1.17 ±
0.05
0.98 ±
0.05
1.18 ± 0.05 1.00 ±
0.05
0.99 ±
0.05
BUN mg/dL Male 16.94 ±
1.66
16.0 ±
2.7
17.1 ± 3.5 15.26 ±
1.69
16.4 ±
2.1
14.52 ±
1.38
15.8 ±
2.3
15.86 ±
1.88
14.7 ±
2.4
16.9 ±
2.9
Female 16.48 ±
1.47
17.5 ±
1.2
15.2 ± 2.0 16.60 ±
1.02
17.3 ±
1.1
16.24 ±
1.39
17.7 ±
1.9
17.14 ±
0.66
16.9 ±
1.9
14.6 ±
1.5
CRE mg/dL Male 0.48 ± 0.07 0.57 ±
0.08
0.59 ±
0.07
0.49 ± 0.03 0.60 ±
0.04
0.48 ±
0.02
0.56 ±
0.03
0.50 ± 0.02 0.56 ±
0.02
0.62 ±
0.07
Female 0.50 ± 0.03 0.63 ±
0.03
0.62 ±
0.04
0.52 ± 0.04 0.64 ±
0.05
0.53 ±
0.05
0.68 ±
0.07
0.53 ± 0.03 0.65 ±
0.05
0.61 ±
0.02
IP mg/dL Male 8.57 ± 0.35 5.96 ±
0.38
5.92 ±
0.53
8.59 ± 0.14 6.16 ±
0.36
8.43 ±
0.42
6.08 ±
0.44
8.76 ± 0.39 6.37 ±
0.59
6.13 ±
0.14
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Female 8.08 ± 0.62 5.69 ±
0.86
4.43 ±
0.28
7.96 ± 0.58 5.17 ±
1.28
8.08 ±
0.50
5.53 ±
0.71
7.95 ± 0.38 5.76 ±
0.79
4.68 ±
0.24
Ca
2+ mg/dL Male 10.53 ±
0.14
10.48 ±
0.15
10.30 ±
0.28
10.47 ±
0.21
10.41 ±
0.20
10.40 ±
0.18
10.26 ±
0.09
10.34 ±
0.25
10.32 ±
0.13
10.39 ±
0.05
Female 10.08 ±
0.25
10.08 ±
0.21
10.48 ±
0.34
10.05 ±
0.22
10.19 ±
0.31
10.03 ±
0.32
10.13 ±
0.22
9.81 ± 0.18 10.20 ±
0.22
10.21 ±
0.28
Na
+ mmol/
L
Male 148.2 ± 0.8 145.3 ±
0.9
143.9 ±
1.2
148.2 ± 0.8 144.7 ±
1.0
148.2 ±
1.3
144.5 ±
0.8
148.6 ± 0.9 145.3 ±
1.3
143.2 ±
0.7
Female 146.2 ± 1.3 145.0 ±
0.9
141.9 ±
1.1
145.2 ± 2.4 144.1 ±
1.2
143.8 ±
0.8
143.5 ±
1.3
144.0 ± 1.0 143.5 ±
0.9
142.0 ±
1.1
K
+ mmol/
L
Male 4.82 ± 0.13 4.32 ±
0.18
4.57 ±
0.23
4.71 ± 0.22 4.19 ±
0.17
4.75 ±
0.12
4.36 ±
0.20
4.72 ± 0.14 4.31 ±
0.21
4.37 ±
0.25
Female 4.71 ± 0.16 3.99 ±
0.15
3.99 ±
0.24
4.52 ± 0.16 4.36 ±
1.08
4.53 ±
0.11
4.20 ±
1.08
4.53 ± 0.43 4.04 ±
0.29
3.96 ±
0.32
Cl
- mmol/
L
Male 108.8 ± 0.4 105.7 ±
0.7
104.5 ±
1.2
108.4 ± 1.1 105.0 ±
1.8
108.2 ±
0.8
106.1 ±
0.9
108.6 ± 0.5 105.2 ±
1.1
103.5 ±
1.0
Female 109.2 ± 0.8 106.5 ±
1.4
104.6 ±
0.9
109.2 ± 0.8 107.1 ±
0.7
108.0 ±
1.2
106.4 ±
0.9
108.2 ± 0.8 105.9 ±
1.1
104.7 ±
1.5
*AST (Aspartate aminotransferase), ALT (Alanine aminotransferase), ALP (Alkaline phosphatase), CPK (Creatine phosphokinase), BIL (Total bilirubin), GLU (Glucose),
CHO (Total cholesterol), TG (Triglyceride), PRO (Total protein), ALB (Albumin), A/G ratio (Albumin/Globulin ratio), BUN (Blood urea nitrogen), CRE (Creatinine), IP
(Inorganic phosphorus), Ca
2+ (Calcium ion), Na
+ (Sodium ion), K
+ (Potassium ion), Cl
- (Chloride ion).
Values are mean ± SD (n = 5 (4 weeks) or 10 (26 weks)/sex/dose). P < 0.05 compare with normal group.
Table 5 Absolute & relative organ weights in rats orally treated with PM012
Dose (mg/kg)
Parameter Sex 0 500 1000 2000
4 Weeks 26 Weeks Recovery 4 Weeks 26 Weeks 4 Weeks 26 Weeks 4 Weeks 26 Weeks Recovery
Body
weight
a)
Male 326.79 ±
18.46
484.71 ±
33.01
502.94 ±
17.59
321.28 ±
20.83
504.38 ±
45.11
330.67 ±
23.75
474.08 ±
46.03
324.80 ±
15.32
468.68 ±
35.08
507.84 ±
32.08
Female 194.35 ±
7.86
268.94 ±
12.88
277.90 ±
26.72
195.07 ±
9.64
270.36 ±
13.17
196.26 ±
12.33
272.81 ±
19.48
195.04 ±
14.05
264.92 ±
17.98
279.89 ±
6.03
Adrenal
grand (Lt.)
Male 0.0266 ±
0.0032
0.0258 ±
0.0025
0.0276 ±
0.0037
0.0260 ±
0.0033
0.0254 ±
0.0031
0.0265 ±
0.0025
0.0245 ±
0.0022
0.0290 ±
0.0011
0.0243 ±
0.0031
0.0271 ±
0.0037
Female 0.0312 ±
0.0025
0.0311 ±
0.0038
0.0309 ±
0.0054
0.0309 ±
0.0023
0.0325 ±
0.0039
0.0333 ±
0.0025
0.0313 ±
0.0056
0.0314 ±
0.0038
0.0310 ±
0.0050
0.0326 ±
0.0053
% to body
weight
Male 0.0082 ±
0.0014
0.0054 ±
0.0007
0.0055 ±
0.0007
0.0081 ±
0.0009
0.0050 ±
0.0005
0.0080 ±
0.0005
0.0052 ±
0.0006
0.0089 ±
0.0007
0.0052 ±
0.0006
0.0053 ±
0.0005
Female 0.0161 ±
0.0016
0.0115 ±
0.0013
0.0112 ±
0.0022
0.0158 ±
0.0008
0.0120 ±
0.0013
0.0170 ±
0.0010
0.0115 ±
0.0019
0.0162 ±
0.0023
0.0117 ±
0.0020
0.0117 ±
0.0019
Adrenal
grand (Rt.)
Male 0.0274 ±
0.0015
0.0247 ±
0.0027
0.0289 ±
0.0025
0.0255 ±
0.0015
0.0252 ±
0.0030
0.0246 ±
0.0046
0.0224 ±
0.0034
0.0264 ±
0.0026
0.0246 ±
0.0026
0.0278 ±
0.0054
Female 0.0305 ±
0.0023
0.0295 ±
0.0030
0.0296 ±
0.0059
0.0308 ±
0.0045
0.0306 ±
0.0033
0.0305 ±
0.0019
0.0301 ±
0.0052
0.0313 ±
0.0041
00287 ±
0.0042
0.0314 ±
0.0048
% to body
weight
Male 0.0084 ±
0.0008
0.0051 ±
0.0006
0.0057 ±
0.0005
0.0080 ±
0.0003
0.0050 ±
0.0003
0.0074 ±
0.0012
0.0048 ±
0.0009
0.0081 ±
0.0009
0.0053 ±
0.0006
0.0055 ±
0.0009
Female 0.0157 ±
0.0013
0.0110 ±
0.0013
0.0108 ±
0.0026
0.0158 ±
0.0020
0.0113 ±
0.0010
0.0156 ±
0.0017
0.0110 ±
0.0019
0.0160 ±
0.0019
0.0109 ±
0.0018
0.0112 ±
0.0018
Pituitary
grand
Male ND
b) 0.0128 ±
0.0010
0.0135 ±
0.0017
ND
b) 0.0126 ±
0.0011
ND
b) 0.0126 ±
0.0013
ND
b) 0.0124 ±
0.0009
0.0135 ±
0.0014
Female ND
b) 0.0151 ±
0.0017
0.0153 ±
0.0011
ND
b) 0.0150 ±
0.0022
ND
b) 0.0170 ±
0.0042
ND
b) 0.0143 ±
0.0021
0.0160 ±
0.0017
% to body
weight
Male ND
b) 0.0026 ±
0.0002
0.0027 ±
0.0004
ND
b) 0.0025 ±
0.0002
ND
b) 0.0027 ±
0.0002
ND
b) 0.0027 ±
0.0001
0.0027 ±
0.0002
Female ND
b) 0.0056 ±
0.0005
0.0056 ±
0.0007
ND
b) 0.0055 ±
0.0009
ND
b) 0.0062 ±
0.0015
ND
b) 0.0054 ±
0.0009
0.0057 ±
0.0005
Thymus Male 0.4132 ±
0.0579
0.1887 ±
0.0403
0.1668 ±
0.0116
0.5040 ±
0.0841
0.2201 ±
0.0349
0.4522 ±
0.0657
0.2055 ±
0.0585
0.4942 ±
0.0904
0.1981 ±
0.0361
0.1520 ±
0.0308
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Page 12 of 16Table 5 Absolute & relative organ weights in rats orally treated with PM012 (Continued)
Female 0.2837 ±
0.0195
0.1380 ±
0.0191
0.1320 ±
0.0144
0.3389 ±
0.0336
0.1418 ±
0.0126
0.3124 ±
0.0420
0.1535 ±
0.0347
0.3372 ±
0.0316
0.1533 ±
0.0233
0.1748 ±
0.0180**
% to body
weight
Male 0.1269 ±
0.0197
0.0388 ±
0.0074
0.0332 ±
0.0022
0.1583 ±
0.0338
0.0437 ±
0.0059
0.1378 ±
0.0261
0.0433 ±
0.0111
0.1515 ±
0.0229
0.0424 ±
0.0076
0.0302 ±
0.0073
Female 0.1462 ±
0.0121
0.0515 ±
0.0083
0.0478 ±
0.0070
0.1739 ±
0.0168**
0.0527 ±
0.0063
0.1588 ±
0.0146
0.0563 ±
0.0126
0.1729 ±
0.0095**
0.0580 ±
0.0088
0.0624 ±
0.0057**
Prostate Male 0.2664 ±
0.0587
0.5802 ±
0.1913
0.5616 ±
0.1757
0.3106 ±
0.1454
0.6464 ±
0.1822
0.3022 ±
0.1208
0.5570 ±
0.1379
0.2706 ±
0.0913
0.6609 ±
0.1472
0.5776 ±
0.0680
% to body
weight
0.0811 ±
0.0150
0.1215 ±
0.0438
0.1109 ±
0.0312
0.0950 ±
0.0412
0.1276 ±
0.0318
0.0921 ±
0.0389
0.1181 ±
0.0294
0.0825 ±
0.0256
0.1408 ±
0.0278
0.1141 ±
0.0152
Testis (Lt.) Male 1.8696 ±
0.0630
2.0628 ±
0.1010
2.2032 ±
0.0711
1.8118 ±
0.2120
2.1428 ±
0.1616
1.7334 ±
0.2977
1.9960 ±
0.1191
1.8244 ±
0.0591
2.1109 ±
0.1282
2.0692 ±
0.1961
% to body
weight
0.5739 ±
0.0444
0.4272 ±
0.0342
0.4385 ±
0.0211
0.5628 ±
0.0395
0.4264 ±
0.0331
0.5235 ±
0.0758
0.4242 ±
0.0432
0.5628 ±
0.0349
0.4522 ±
0.0376
0.4075 ±
0.0315
Testis (Rt.) Male 1.8672 ±
0.0834
2.0352 ±
0.1580
2.1622 ±
0.0698
1.8232 ±
0.2055
2.1153 ±
0.1467
1.7288 ±
0.2737
2.0206 ±
0.1294
1.8008 ±
0.0563
2.0990 ±
0.1063
2.0372 ±
0.1672
% to body
weight
0.5734 ±
0.0512
0.4218 ±
0.0453
0.4304 ±
0.0209
0.5664 ±
0.0357
0.4215 ±
0.0376
0.5226 ±
0.0718
0.4302 ±
0.0524
0.5553 ±
0.0288
0.4500 ±
0.0388
0.4021 ±
0.0375
Epididymis
(Lt.)
Male ND
b) 0.7142 ±
0.0282
0.7672 ±
0.0424
ND
b) 0.7532 ±
0.0594
ND
b) 0.7185 ±
0.0632
ND
b) 0.7396 ±
0.0401
0.7240 ±
0.0396
% to body
weight
ND
b) 0.1478 ±
0.0092
0.1529 ±
0.0126
ND
b) 0.1499 ±
0.0120
ND
b) 0.1526 ±
0.0181
ND
b) 0.1584 ±
0.0120
0.1429 ±
0.0097
Epididymis
(Rt.)
Male ND
b) 0.7352 ±
0.0372
0.7620 ±
0.0299
ND
b) 0.7572 ±
0.0604
ND
b) 0.7429 ±
0.0493
ND
b) 0.7501 ±
0.0461
0.7184 ±
0.0322
% to body
weight
ND
b) 0.1523 ±
0.0131
0.1517 ±
0.0090
ND
b) 0.1507 ±
0.0121
ND
b) 0.1578 ±
0.0157
ND
b) 0.1606 ±
0.0127
0.1417 ±
0.0062
Ovary (Lt.) Female 0.0443 ±
0.0089
0.0388 ±
0.0120
0.0302 ±
0.0085
0.0434 ±
0.0037
0.0397 ±
0.0093
0.0452 ±
0.0077
0.0354 ±
0.0066
0.0411 ±
0.0051
0.0403 ±
0.0132
0.0317 ±
00129
% to body
weight
0.0227 ±
0.0040
0.0143 ±
0.0040
0.0108 ±
0.0023
0.0223 ±
0.0024
0.0146 ±
0.0031
0.0230 ±
0.0035
0.0131 ±
0.0033
0.0210 ±
0.0020
0.0151 ±
0.0044
0.0114 ±
0.0048
Ovary (Rt.) Female 0.0453 ±
0.0047
0.0375 ±
0.0087
0.0305 ±
0.0134
0.0430 ±
0.0067
0.0413 ±
0.0102
0.0454 ±
0.0081
0.0346 ±
0.0079
0.0456 ±
0.0071
0.0360 ±
0.0105
0.0296 ±
0.0078
% to body
weight
0.0233 ±
0.0023
0.0139 ±
0.0031
0.0107 ±
0.0035
0.0221 ±
0.0036
0.0153 ±
0.0037
0.0231 ±
0.0035
0.0127 ±
0.0031
0.0234 ±
0.0035
0.0135 ±
0.0034
0.0106 ±
0.0029
Uterus Female 0.6020 ±
0.5041
0.7540 ±
0.2803
1.5136 ±
1.7081
0.7301 ±
0.3711
0.7690 ±
0.2454
0.4385 ±
0.1144
0.6901 ±
0.2825
0.4302 ±
0.1316
1.0180 ±
0.7969
0.7328 ±
0.1301
% to body
weight
0.3134 ±
0.2721
0.2805 ±
0.1043
0.5421 ±
0.5875
0.3756 ±
0.1879
0.2866 ±
0.0986
0.2219 ±
0.0471
0.2506 ±
0.0902
0.2244 ±
0.0825
0.3884 ±
0.3038
0.2615 ±
0.0441
Spleen Male 0.7080 ±
0.0403
0.8423 ±
0.1620
0.9244 ±
0.1689
0.7766 ±
0.0442
0.8627 ±
0.1149
0.8082 ±
0.1229
0.8115 ±
0.1162
0.6982 ±
0.1578
0.8396 ±
0.0962
0.9108 ±
0.2680
Female 0.5174 ±
0.0475
0.6023 ±
0.0677
0.5912 ±
0.0969
0.5178 ±
0.0523
0.5904 ±
0.0496
0.5450 ±
0.0515
0.5846 ±
0.0497
0.5438 ±
0.0540
0.5765 ±
0.0545
0.6338 ±
0.0327
% to body
weight
Male 0.2167 ±
0.0048
0.1730 ±
0.0254
0.1838 ±
0.0339
0.2427 ±
0.0232
0.1712 ±
0.0202
0.2436 ±
0.0258
0.1712 ±
0.0173
0.2138 ±
0.0418
0.1796 ±
0.0205
0.1781 ±
0.0461
Female 0.2665 ±
0.0256
0.2239 ±
0.0219
0.2117 ±
0.0160
0.2655 ±
0.0242
0.2182 ±
0.0115
0.2778 ±
0.0218
0.2152 ±
0.0231
0.2786 ±
0.0136
0.2177 ±
0.0161
0.2264 ±
0.0087
Kidney (Lt.) Male 1.0834 ±
0.0737
1.4412 ±
0.0916
1.5350 ±
0.1345
1.1088 ±
0.1901
1.4725 ±
0.2157
1.1310 ±
0.0947
1.3753 ±
0.1792
1.0716 ±
0.0701
1.4461 ±
0.3356
1.4692 ±
0.2390
Female 0.6434 ±
0.0440
0.7791 ±
0.0439
0.8626 ±
0.0847
0.6320 ±
0.0439
0.7969 ±
0.0477
0.6650 ±
0.0495
0.8142 ±
0.0688
0.6674 ±
0.0675
0.8092 ±
0.0705
0.8742 ±
0.0311
% to body
weight
Male 0.3318 ±
0.0193
0.2978 ±
0.0159
0.3050 ±
0.0219
0.3432 ±
0.0376
0.2910 ±
0.0249
0.3419 ±
0.0083
0.2899 ±
0.0205
0.3299 ±
0.0131
0.3073 ±
0.0569
0.2890 ±
0.0406
Female 0.3312 ±
0.0210
0.2901 ±
0.0188
0.3113 ±
0.0296
0.3238 ±
0.0086
0.2949 ±
0.0128
0.3387 ±
0.0089
0.2988 ±
0.0206
0.3417 ±
0.0114
0.3057 ±
0.0212
0.3124 ±
0.0119
Kidney (Rt.) Male 1.0920 ±
0.0966
1.4783 ±
0.0904
1.5424 ±
0.1388
1.0810 ±
0.1098
1.5046 ±
0.2471
1.1354 ±
0.0658
1.3637 ±
0.1638
1.0760 ±
0.0876
1.3921 ±
0.1399
1.4910 ±
0.2666
Female 0.6700 ±
0.0245
0.7974 ±
0.0511
0.8416 ±
0.0896
0.6542 ±
0.0316
0.8195 ±
0.0634
0.6956 ±
0.0681
0.8177 ±
0.0871
0.6604 ±
0.0610
0.8213 ±
0.0652
0.8740 ±
0.0535
% to body
weight
Male 0.3345 ±
0.0286
0.3055 ±
0.0175
0.3064 ±
0.0217
0.3361 ±
0.0184
0.2969 ±
0.0260
0.3437 ±
0.0108
0.2879 ±
0.0218
0.3310 ±
0.0159
0.2969 ±
0.0165
0.2931 ±
0.0453
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Page 13 of 16luteum cyst observed in female ovaries are all sponta-
neous lesions [38,39,41]. All of these conditions are
readily detected in old rats and were not considered to
be changes triggered by the administration of PM012
based on the comparison to the vehicle control group.
Other anomalies were determined to be unrelated to
the administration of PM012. In females, an enlarge-
ment of uterine cavity, hydrometra, was observed in
similar frequency in the vehicle control group, and
because no other lesions were observed in the uterus,
such as in the endometrial epithelium or myometrial
area, it was judged that these changes were not triggered
by the administration of PM012 and were considered as
changes related to the regular sexual cycle [41]. No cel-
lular reaction to a hemorrhage in the parenchyma of the
thymus was observed, and a hemorrhage is a lesion that
i so f t e ns e e na f t e re t h e r i z a t i o na n dt h e r e f o r ew a sn o t
considered to be an effect of the administration of
PM012 [41]. A benign ganglioneuroma derived from
adrenal medulla cells and consisting of histopathologi-
cally proliferative big ganglion cells and interstitial ner-
vous tissue such as Schwann cells, satellite cells and
nerve fibers was observed in a male treated with 2,000
mg/kg/day. The tumors observed in this study were
observed to be over 80% ganglioneuromas and the rest
had the histological features of pheochromocytomas. In
this case, it is reasonable to diagnose these tumors as
ganglioneuromas rather than complex pheochromocyto-
mas, as this type of tumors is seldom found in old rats
[38]. The fibroadenoma observed in the mammary gland
of the skin in a female from the middle dose group was
a benign tumor derived from the mammary epithelium
and connective tissue, which is observed at a high fre-
quency in rats and was judged to have occurred sponta-
neously and therefore was unrelated to treatment with
PM012 [38,39]. We also found that the 4- or 26-week
Table 5 Absolute & relative organ weights in rats orally treated with PM012 (Continued)
Female 0.3451 ±
0.0156
0.2967 ±
0.0179
0.3030 ±
0.0199
0.3355 ±
0.0096
0.3032 ±
0.0199
0.3539 ±
0.0160
0.2997 ±
0.0257
0.3382 ±
0.0090
0.3104 ±
0.0204
0.3125 ±
0.0224
Heart Male 1.1572 ±
0.0898
1.6088 ±
0.1665
1.5266 ±
0.1471
1.1302 ±
0.2075
1.5934 ±
0.1625
1.1730 ±
0.0850
1.4677 ±
0.1040
1.1562 ±
0.0871
1.5236 ±
0.1646
1.5334 ±
0.2367
Female 0.7574 ±
0.0447
0.9366 ±
0.0652
0.9298 ±
0.1196
0.7590 ±
0.0380
0.9729 ±
0.0742
0.7254 ±
0.0599
0.9469 ±
0.0530
0.7158 ±
0.0575
1.0124 ±
0.3391
0.9704 ±
0.0845
% to body
weight
Male 0.3543 ±
0.0229
0.3317 ±
0.0228
0.3034 ±
0.0256
0.3499 ±
0.0445
0.3160 ±
0.0185
0.3551 ±
0.0177
0.3118 ±
0.0324
0.3560 ±
0.0208
0.3250 ±
0.0230
0.3010 ±
0.0324
Female 0.3896 ±
0.0119
0.3484 ±
0.0209
0.3344 ±
0.0242
0.3893 ±
0.0152
0.3601 ±
0.0259
0.3705 ±
0.0346
0.3477 ±
0.0142
0.3683 ±
0.0374
0.3845 ±
0.1360
0.3465 ±
0.0266
Lung Male 1.5656 ±
0.0698
1.9947 ±
0.1779
2.0066 ±
0.1561
1.4874 ±
0.1229
2.0049 ±
0.1510
1.5250 ±
0.1239
1.8534 ±
0.1209
1.5416 ±
0.1092
1.9613 ±
0.1305
1.8042 ±
0.1591
Female 1.1890 ±
0.0432
1.4361 ±
0.1088
1.4584 ±
0.1603
1.2182 ±
0.1431
1.4594 ±
0.0892
1.2164 ±
0.1588
1.4234 ±
0.0721
1.1466 ±
0.0518
1.4478 ±
0.1077
1.4262 ±
0.1322
% to body
weight
Male 0.4797 ±
0.0204
0.4114 ±
0.0208
0.3987 ±
0.0234
0.4637 ±
0.0366
0.3982 ±
0.0178
0.4610 ±
0.0128
0.3923 ±
0.0204
0.4744 ±
0.0180
0.4205 ±
0.0415
0.3571 ±
0.0440
Female 0.6121 ±
0.0203
0.5337 ±
0.0229
0.5264 ±
0.0574
0.6234 ±
0.0522
0.5403 ±
0.0305
0.6207 ±
0.0833
0.5233 ±
0.0339
0.5891 ±
0.0283
0.5469 ±
0.0270
0.5094 ±
0.0439
Brain Male ND
b) 2.0641 ±
0.0562
2.0344 ±
0.0501
NDb) 2.0215 ±
0.0849
NDb) 1.9862 ±
0.0473
NDb) 2.0204 ±
0.0423
2.0450 ±
0.0802
Female ND
b) 1.8062 ±
0.0368
1.8284 ±
0.0730
NDb) 1.8646 ±
0.0732
NDb) 1.8016 ±
0.0678
NDb) 1.8069 ±
0.0602
1.8722 ±
0.0673
% to body
weight
Male ND
b) 0.4275 ±
0.0298
0.4048 ±
0.0137
NDb) 0.4026 ±
0.0255
NDb) 0.4220 ±
0.0351
NDb) 0.4329 ±
0.0277
0.4042 ±
0.0335
Female ND
b) 0.6726 ±
0.0258
0.6629 ±
0.0681
NDb) 0.6902 ±
0.0214
NDb) 0.6628 ±
0.0431
NDb) 0.6841 ±
0.0382
0.6695 ±
0.0368
Liver Male 9.5912 ±
0.7911
11.8528 ±
1.1643
12.6104 ±
1.7035
9.3626 ±
0.9629
12.5935 ±
2.2636
10.1466 ±
0.5700
11.1793 ±
1.7555
9.5052 ±
0.5582
11.0740 ±
0.9159
13.0788 ±
2.8997
Female 5.5920 ±
0.5099
6.4589 ±
0.7810
6.4812 ±
0.6049
5.5784 ±
0.5334
6.8322 ±
1.1330
5.5102 ±
0.3767
6.8610 ±
1.7458
5.5738 ±
0.5615
6.6866 ±
0.5558
6.6626 ±
0.9795
% to body
weight
Male 2.9356 ±
0.1935
2.4422 ±
0.1178
2.5046 ±
0.3008
2.9083 ±
0.1159
2.4815 ±
0.2634
3.0727 ±
0.1101
2.3528 ±
0.2271
2.9256 ±
0.0668
2.3638 ±
0.1116
2.5611 ±
0.4535
Female 2.8812 ±
0.2921
2.3981 ±
0.2116
2.3332 ±
0.0680
2.8595 ±
0.2334
2.5241 ±
0.3756
2.8115 ±
0.1862
2.4970 ±
0.4764
2.8554 ±
0.1547
2.5322 ±
0.2457
2.3763 ±
0.3002
a) Represents body weights right before necropsy, after fasting.
b) ND, not determined.
Values are mean ± SD (n = 5 (4 weeks or recovery) or 10 (26 weks)/sex/dose). P < 0.05 compare with normal group.
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Page 14 of 16repeated oral administration of PM012 in male and
female rats induced an increase and increasing trend in
the weight of the thymus in the female treatment groups
(main and recovery groups), but the change was judged
to be toxicologically insignificant.
Conclusion
Given our evaluation of all the data, the no observed
adverse effects levels (NOAEL) of PM012 was deter-
mined to be 2,000 mg/kg/day for both sexes, and the
target organ was not identified. We conclude that
PM012 has potential for use in the treatment of the Alz-
heimer’s disease without serious adverse effects.
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